Cost reduction levers PSG has a track record of generating over $7 billion in savings for clients across more than 20 million lives, highlighting strong cross-client cost containment opportunities in drug spend management, rebates, and formulary optimization workflows that can be expanded with payer and healthcare system prospects.

Specialty drug focus PSG emphasizes specialty drug benefits and trends, evidenced by its 2023 and 2024 reports and participation in specialty drug summit discussions, signaling a strong foothold with health plans and employers seeking advanced specialty drug cost management and coverage design.

Analytics driven With a technology-powered approach leveraging analytics and proprietary tools (Artemetrx, Looker, Meditech, Oracle, Epic), there are upsell opportunities around data-enabled decision support, predictive analytics, and real-time cost management dashboards for broader client segments.

Strategic leadership Recent leadership appointments and growth in operations signal readiness to scale via enhanced procurement strategy, financial analytics, and consulting capabilities, offering a pathway to engage larger health systems and multi-employer organizations seeking integrated pharmacy programs.

Acquisition backdrop PSG’s connection to Omnicell through the 340B Link business and its EPIC affiliation present collaboration prospects for integrated medication management, 340B optimization, and tech-enabled pharmacy workflow improvements within combined healthcare ecosystems.